Log Out

Johnson & Johnson (NYSE:JNJ) Stock Position Reduced by Fiera Capital Corp

Defense World · Jan 29, 2023 08:21

Fiera Capital Corp cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 7,386,326 shares of the company's stock after selling 436,532 shares during the period. Johnson & Johnson comprises approximately 3.9% of Fiera Capital Corp's holdings, making the stock its 5th largest position. Fiera Capital Corp owned approximately 0.28% of Johnson & Johnson worth $1,085,619,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Morton Brown Family Wealth LLC grew its position in Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company's stock worth $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $39,000. First Bank & Trust grew its position in Johnson & Johnson by 69.6% in the second quarter. First Bank & Trust now owns 380 shares of the company's stock worth $67,000 after acquiring an additional 156 shares in the last quarter. Heritage Wealth Management LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $84,000. Finally, Timber Creek Capital Management LLC grew its position in Johnson & Johnson by 225.0% in the third quarter. Timber Creek Capital Management LLC now owns 650 shares of the company's stock worth $106,000 after acquiring an additional 450 shares in the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Get Johnson & Johnson alerts:

Insider Buying and Selling

In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares in the company, valued at approximately $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company's stock, valued at approximately $2,707,775. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock worth $40,960,735 in the last quarter. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.4 %

Shares of JNJ stock opened at $168.23 on Friday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The stock has a market cap of $439.83 billion, a price-to-earnings ratio of 24.96, a P/E/G ratio of 2.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm has a fifty day moving average of $175.63 and a 200-day moving average of $170.96.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.94%. The company had revenue of $23.71 billion during the quarter, compared to analysts' expectations of $23.90 billion. During the same quarter in the prior year, the company posted $2.13 EPS. The business's revenue was down 4.4% on a year-over-year basis. On average, equities research analysts forecast that Johnson & Johnson will post 10.52 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson's dividend payout ratio is 67.06%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a "strong-buy" rating for the company. Raymond James decreased their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, October 19th. Barclays began coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an "equal weight" rating and a $175.00 price objective for the company. Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a "neutral" rating for the company in a report on Friday, October 14th. Finally, SVB Leerink decreased their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating for the company in a report on Friday, January 20th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $182.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.